logo
calendar30 Yanvar 2021
view30
Main language:English

PATHOPHYSIOLOGY OF PARKINSON'S DISEASE AND THE EFFICIENCY OF ITS TREATMENT

Field of Science:
pdf

61b9bee0ea329.pdf

PDF

RE-HEALTH

RE-HEALTH

Publish Articlesee more

ARTICLE ANNOTATION

quote
Parkinsonism is a secondary neurodegenerative disease characterized by degeneration of dopaminergic neurons, accompanied by motor and non-motor symptoms. Primary neurodegenerative disease Alzheimer’s is a syndrome of mental retardation and memory loss. Parkinson's is one of the most common diseases in the world. It is mainly found in people over 50 years of age. According to modern statistics, about 100 million people are infected with Parkinson's disease. Of these, 40% are in North Africa and the Arab world as a whole, and about 14% are Ashkenazi Jews. This article discusses the pathophysiology of Parkinsonism and its treatment.

AUTHORS

Science ID: FAN-1125-0025

Tags

# паркинсонизм# parkinsonism# дофаминергический# дегенеративный# нейродегенеративный# синдром Альцгеймера# dopaminergic# degeneration# neurodegenerative# Alzheimer's syndrome# Parkinsonizm# dopaminergik# degeneratsiya# neyrodegenerativ# Altsgeymer sindromi

OTHER ARTICLES IN THIS JOURNAL

Rate Article

0
0 ratings
5
4
3
2
1

Article Identifiers

ROI:

https://eroi.uz/11.0082/A0121-0088

DOI:

Not Available

References

1. Connolly BS, Lang AE (23–30 April 2014). "Pharmacological treatment of Parkinson disease: a review". JAMA. 311 (16): 1670–83. doi:10.1001/jama.2014.3654. PMID 24756517.

2. The non-motor and non-dopaminergic fratures of PD. Parkinson's Disease: Non-Motor and Non-Dopaminergic Features. Olanow, C. Warren., Stocchi, Fabrizio., Lang, Anthony E. Wiley-Blackwell. 2011. ISBN 978-1405191852.

3. The National Collaborating Centre for Chronic Conditions, ed. (2006). "Symptomatic pharmacological therapy in Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 59–100. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.

4. Zhang J, Tan LC (2016). "Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist". Current Neuropharmacology. 14 (4): 356–63. doi:10.2174/1570159X14666151208114634. PMC 4876591. PMID 26644151.

5. Pedrosa DJ, Timmermann L (2013). "Review: management of Parkinson's disease". Neuropsychiatric Disease and Treatment. 9: 321–40. doi:10.2147/NDT.S32302. PMC 3592512. PMID 23487540.

6. The National Collaborating Centre for Chronic Conditions, ed. (2006). "Palliative care in Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 147–51. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.

7. Wichmann, T. (2019). Changing views of the pathophysiology of Parkinsonism. Movement Disorders. doi:10.1002/mds.27741 .

8. Marsili, L., Bologna, M., Kojovic, M., Berardelli, A., Espay, A. J., & Colosimo, C. (2019). Dystonia in atypical parkinsonian disorders. Parkinsonism & Related Disorders. doi:10.1016/j.parkreldis.2019.07.030.

9. S.M. Boesch, G.K. Wenning, G. Ransmayr, W. Poewe, Dystonia in multiple system atrophy, J. Neurol. Neurosurg. Psychiatry 72 (2002) 300–303.

10. W. Poewe, G.K. Wenning, The natural history of Parkinson's disease, Ann. Neurol. 44 (1998) 1–9.